U.S., Aug. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07111260) titled 'Efficacy of pHA130 Hemoadsorption for 4 Hours (p4H Study)' on July 28.
Brief Summary: This is an open-label, randomized, crossover study to evaluate the efficacy of extending the duration of hemoadsorption (HA) combined with hemodialysis (HD) from 2 hours to 4 hours for clearing protein-bound uremic toxins, such as Indoxyl Sulfate (IS), in stable maintenance hemodialysis patients. Patients will be randomized to receive either 2-hour HA or 4-hour HA once a week for 8 weeks, then cross over to the other treatment for another 8 weeks after a 2-week washout period. The primary endpoint is the reduction rate of IS.
Study Start Date: July...